Aficamten vs Mavacamten
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertrophic Cardiomyopathy
Shared mechanism: Cardiac myosin (inhibitor) · full Hypertrophic Cardiomyopathy pipeline
Aficamten · Myqorzo
Marketed by Cytokinetics and partners
NCT05767346 · Phase 3 · completed
This randomized, triple-blind, active-controlled Phase 3 trial (n=175) compared aficamten with the beta-blocker metoprolol succinate in adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint, change in peak oxygen uptake on exercise testing at 24 weeks, improved significantly more with aficamten than metoprolol (mean difference 2.30 mL/kg/min, p<0.0001).
Next expected readout: December 2026 · NCT07600177 (registry estimate)
Reported efficacy
Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186) (met)
Result source: NCT05767346
Mavacamten · Camzyos
Marketed by Bristol-Myers Squibb
NCT03470545 · Phase 3 · completed
EXPLORER-HCM was a randomized, double-blind, placebo-controlled Phase 3 trial in 251 adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint was a composite clinical response built from peak oxygen consumption and NYHA class at week 30: 37% with mavacamten vs 17% with placebo (difference 19.4%, 95% CI 8.7 to 30.1, p=0.0005), so the primary was met. Source: the peer-reviewed paper (Olivotto et al., Lancet 2020).
Next expected readout: December 2027 · NCT07004972 (registry estimate)
Reported efficacy
Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants (met)
Result source: NCT04349072
Results for Hypertrophic Cardiomyopathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aficamten's landscape · Mavacamten's landscape